Syndax制药 SNDX 深 沪
等待开盘 09-24 09:30:00 美东时间
14.85
-0.040
-0.27%
华盛通- 最 高15.125
- 今 开14.81
- 成交量 130.14万股
- 最 低 14.68
- 昨 收 14.89
- 总市值 12.79亿
- 52周最高 22.50
- 市盈率 静 --
- 换手率 1.51%
- 52周最低 8.58
- 委 比 -55.31%
- 总股本 8614.19万
- 历史最高 29.86
- 量 比 0.61
- 振 幅 2.99%
- 历史最低 3.39
- 每 手 1
- 风险率 2.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
BTIG Reiterates Buy on Syndax Pharmaceuticals, Maintains $56 Price Target
BTIG analyst Justin Zelin reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $56 price target.
09-20 01:11
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
Syndax Pharmaceuticals announced that revumenib has been included in the NCCN Guidelines as a category 2A recommendation for relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation. This update follows positive results from the AUGMENT-101 trial, published in *Blood*. The Company has submitted a supplemental New Drug Application (sNDA) for revumenib in R/R mNPM1 AML, which received Priority Review from the FDA with a PDUFA targe...
09-19 11:00
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
Syndax Pharmaceuticals (NASDAQ:SNDX) underwent analysis by 5 analysts in the la...
09-04 20:02
Guggenheim Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $34
Guggenheim analyst Bradley Canino initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces Price Target of $34.
09-04 19:43
美股大行评级 | 潜在涨幅345.51%！BTIG上调Syndax Pharmaceuticals目标价至56美元，维持"买入"评级
今日重点评级关注：BTIG：维持Syndax Pharmaceuticals"买入"评级，目标价从43美元升至56美元；花旗：维持Syndax Pharmaceuticals"买入"评级，目标价从46美元升至51美元
08-06 09:30
Syndax jumps after Q2 beat; Citi issues upside catalyst watch
Syndax Pharmaceuticals (NASDAQ:SNDX) added ~21% in the premarket on Tuesday after the cancer drugmaker reported better-than-expected Q2 2025 financials, prompting Citi to issue a 90-day upside catalys...
08-06 01:20
BTIG Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $56
BTIG analyst Justin Zelin maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $43 to $56.
08-06 00:29
Syndax Pharmaceuticals Q2 EPS $(0.83) Beats $(1.00) Estimate, Sales $37.958M Beat $26.780M Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(1.00) by 17.33 percent. This is a 3.75 percent decrease over losses of $(0.80) per share
08-05 04:04
